 Chemotherapy and systemic therapy: Prior therapy with ALK inhibitors is permissible. Patients may not have received prior MEK inhibitors or any other tyrosine kinase inhibitor including EGFR inhibitors of any kind. Patients may have received vaccines, immunotherapy or other agents that are not MEKtyrosine kinase inhibitors in the adjuvant setting or for advanced or metastatic disease. 